Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11349530 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1416458 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor-produced immune regulatory factors as a therapeutic target in cancer treatment.
Front Immunol
August 2024
Department of Molecular Pharmacology and Radiobiology, Pirogov Russian National Research Medical University, Moscow, Russia.
Purpose: ARO-HIF2 is an siRNA drug designed to selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). The aims of this Phase 1 study (AROHIF21001) were to evaluate safety, tolerability, pharmacokinetics, and establish a recommended Phase 2 dose.
Patients And Methods: Subjects with ccRCC and progressive disease after at least 2 prior therapies that included VEGF and immune checkpoint inhibitors were progressively enrolled into dose-escalation cohorts of ARO-HIF2 administered intravenously at 225, 525, or 1,050 mg weekly.
GPX3 supports ovarian cancer tumor progression and promotes expression of GDF15.
bioRxiv
January 2024
Department of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.
Objective: We previously reported that high expression of the extracellular glutathione peroxidase GPX3 is associated with poor patient outcome in ovarian serous adenocarcinomas, and that GPX3 protects ovarian cancer cells from oxidative stress in culture. Here we tested if GPX3 is necessary for tumor establishment and to identify novel downstream mediators of GPX3's pro-tumorigenic function.
Methods: GPX3 was knocked-down in ID8 ovarian cancer cells by shRNA to test the role of GPX3 in tumor establishment using a syngeneic IP xenograft model.
GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15.
Gynecol Oncol
June 2024
Department of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA. Electronic address:
Objective: We previously reported that high expression of the extracellular glutathione peroxidase GPX3 is associated with poor patient outcome in ovarian serous adenocarcinomas, and that GPX3 protects ovarian cancer cells from oxidative stress in culture. Here we tested if GPX3 is necessary for tumor establishment in vivo and to identify novel downstream mediators of GPX3's pro-tumorigenic function.
Methods: GPX3 was knocked-down in ID8 ovarian cancer cells by shRNA to test the role of GPX3 in tumor establishment using a syngeneic IP xenograft model.
The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer.
Exp Hematol Oncol
September 2023
Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Article Synopsis
- PTX3 is a protein that can help or hurt cancer, especially in a tough type called triple negative breast cancer (TNBC).
- Researchers studied how PTX3 behaves in TNBC cells and found that more PTX3 makes the cancer grow faster and act more aggressive.
- Decreasing PTX3 levels makes TNBC cells less aggressive, suggesting it plays a big role in how the cancer develops.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!